Mirae Asset Global ETFs Holdings’s Werewolf Therapeutics HOWL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-18,651
Closed -$18.1K 3106
2025
Q1
$18.1K Buy
18,651
+780
+4% +$1.02K ﹤0.01% 2992
2024
Q4
$26.4K Buy
17,871
+760
+4% +$1.55K ﹤0.01% 2982
2024
Q3
$36.3K Buy
+17,111
New +$38.9K ﹤0.01% 2971

Other funds holding HOWL

Mirae Asset Global ETFs Holdings's HOWL Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 18,651 shares — an estimated $18.1K sold.

Mirae Asset Global ETFs Holdings first reported a position in HOWL in Q3 2024 and held it in 3 quarters. The position peaked at $36.3K in Q3 2024. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 18,651 Werewolf Therapeutics shares in Q2 2025, an estimated $18.1K.
  • Mirae Asset Global ETFs Holdings first reported a position in Werewolf Therapeutics in Q3 2024 and held it in 3 quarters.
  • Mirae Asset Global ETFs Holdings's Werewolf Therapeutics position peaked at $36.3K in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.